The stock of Jaguar Health Inc (JAGX) has gone down by -6.56% for the week, with a -6.25% drop in the past month and a -43.85% drop in the past quarter. The volatility ratio for the week is 13.45%, and the volatility levels for the past 30 days are 15.99% for JAGX. The simple moving average for the last 20 days is 12.35% for JAGX stock, with a simple moving average of -70.80% for the last 200 days.
Is It Worth Investing in Jaguar Health Inc (NASDAQ: JAGX) Right Now?
The 36-month beta value for JAGX is also noteworthy at 1.39. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for JAGX is 165.52M, and at present, short sellers hold a 4.50% of that float. The average trading volume of JAGX on April 08, 2024 was 40.57M shares.
JAGX) stock’s latest price update
The stock of Jaguar Health Inc (NASDAQ: JAGX) has increased by 8.53 when compared to last closing price of 0.08. Despite this, the company has experienced a -6.56% fall in its stock price over the last five trading sessions. Accesswire reported 2024-03-27 that Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide corporate updates.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at 1.62% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.11% of loss for the given period.
Volatility was left at 15.99%, however, over the last 30 days, the volatility rate increased by 13.45%, as shares surge +2.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.21% lower at present.
During the last 5 trading sessions, JAGX fell by -6.56%, which changed the moving average for the period of 200-days by -87.72% in comparison to the 20-day moving average, which settled at $0.0749. In addition, Jaguar Health Inc saw -44.52% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -3.48 for the present operating margin
- 0.73 for the gross margin
The net margin for Jaguar Health Inc stands at -4.23. The total capital return value is set at -0.92. Equity return is now at value -1919.14, with -84.10 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.88 points at debt to capital in total, while cash flow to debt ratio is standing at -0.92. The debt to equity ratio resting at 7.3. The interest coverage ratio of the stock is -5.31.
Currently, EBITDA for the company is -31.53 million with net debt to EBITDA at -0.97. When we switch over and look at the enterprise to sales, we see a ratio of 4.92. The receivables turnover for the company is 4.47for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.
Conclusion
In summary, Jaguar Health Inc (JAGX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
